Celldex: 'Strong Buy' Barzolvolimab Dilanjutkan Hingga Rilis Data CSU Kuartal 4 2026 (NASDAQ:CLDX)
· seekingalpha.com
Celldex (CLDX) tetap menjadi Strong Buy seiring barzolvolimab mencapai katalis Fase 3 CSU dan CDX-622 menunjukkan kemajuan; lihat linimasa data 2026 dan risiko dilusi—baca sekarang.
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you ...